Migraine is a frequent brain illness that can be debilitating. Headache accounts for 4.4 percent of all general practice visits, almost 5% of all medical hospital admissions, and over 20% of neurology outpatient consultations. Migraine affects about 20% of people at some point in their lives, epidemiological research reveal that 4.5% of Western Europe's population suffers from headaches at least 15 days per month, while global studies suggest that about 1% of the world's population suffers from chronic migraine.
Frequently Asked Questions
The market is segmented based on Segmentation, By Types (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over the Counter), Type (Branded and Generic), End-User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) – Industry Trends and Forecast to 2032
.
The Global Migraine Treatment Market size was valued at USD 3.07 USD Billion in 2024.
The Global Migraine Treatment Market is projected to grow at a CAGR of 8.8% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
